Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients
Status:
Recruiting
Trial end date:
2020-09-25
Target enrollment:
Participant gender:
Summary
The leading cause of death in patients with COVID19 is a severe inflammatory response caused
by a cytokine storm that results in acute respiratory distress syndrome and acute pulmonary
insufficiency, as well as dysfunction of several vital organs. Therefore, preventing the
occurrence of uncontrolled inflammation is the main goal of the ongoing clinical trials.
Chloroquine and tocilizumab, which have the best results, are also prescribed to control
inflammation. But it can be said that treatments are the main source of inflammation.
Inflammasome NLRP3 is one of the mechanisms involved in many severe inflammatory disorders.
Inflammatory activation has already been demonstrated by many viruses. Melatonin, on the
other hand, is a hormone in the body that can inhibit Inflammation NLRP3 in addition to
various anti-inflammatory effects, especially after severe inflammation. Older adults with
lower levels of melatonin and children with maximum levels of melatonin are the risk groups
and low-risk groups for the disease, respectively. In the present study, while measuring
melatonin in patients with COVID19, its effectiveness as a treatment method along with the
common antiviral drug regimen in patients with severe disease will be evaluated.